{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:07:34Z","timestamp":1790942854534,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008120","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,12,8]],"date-time":"2010-12-08T00:00:00Z","timestamp":1291766400000}}],"reference-count":67,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008120.pub2","type":"journal-article","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T14:55:00Z","timestamp":1291042500000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Second-generation antipsychotics for anxiety disorders"],"prefix":"10.1002","author":[{"given":"Anna M","family":"Depping","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Komossa","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,8]]},"reference":[{"key":"10.1002\/14651858.CD008120.pub2-BIB0001|cit1","unstructured":"Bandelow B Bobes J Ahokas A Eggens I Liu S Brecher M Results from a phase III study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder Presented at 7th International Forum of Mood and Anxiety Disorders"},{"issue":"4","key":"10.1002\/14651858.CD008120.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/026988110201600412","article-title":"Efficacy of olanzapine in social anxiety disorder: a pilot study","volume":"16","author":"Barnett","year":"2002","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.4088\/JCP.v66n1016","article-title":"Adjunctive risperidone in generalized anxiety disorder: a double blind, placebo-controlled study","volume":"66","author":"Brawman-Mintzer","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0004|cit4","unstructured":"Eriksson H Mezhebovsky I M\u00e4gi K Chouinard G She F Datto C Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalized anxiety disorder(GAD): results from a double-blind, randomized, placebo-controlled study Poster presented at the 47th American College of Neuropsychopharmacology Annual meeting"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0005|cit5","unstructured":"Joyce M Khan A Atkinson S Eggens I Baldytcheva I Brecher M Efficacy and safety of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder Presented at the 161st Annual meeting of the American Psychiatric Association"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0006|cit6","unstructured":"Katzman M Brawman-Mintzer O Reyes E Olausson B Liu S Brecher M Extended release quetiapine fumarate (Quetiapine XR) monotherapy in maintenance treatment of generalized anxiety disorder (GAD): Efficacy and tolerability results from randomized, placebo-controlled trial Presented at the 161st Annual Meeting of the American Psychiatric"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0007|cit7","unstructured":"Merideth C Curtler A Nejiber A She F Eriksson H Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalized anxiety disorder (GAD) Presented at the 21st Congress of the European College of Neuropsychpharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008120.pub2-BIB0008|cit8","first-page":"41","article-title":"Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Pandina","year":"2007","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopsych.2005.07.005","article-title":"Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study","volume":"59","author":"Pollack","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00213-008-1087-x","article-title":"Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings","volume":"197","author":"Simon","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.pnpbp.2007.06.027","article-title":"Quetiapine as a monotherapy for social anxiety disorder: a placebo controlled study","volume":"31","author":"Vaishnavi","year":"2007","journal-title":"Progress in Neuropsychopharmacology & Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008120.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/da.10137","article-title":"Preliminary experience with adjunctive risperidone in patients receiving selective serotonin reuptake inhibitors","volume":"19","author":"Adson","year":"2004","journal-title":"Depression and Anxiety"},{"issue":"1","key":"10.1002\/14651858.CD008120.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2004.11.007","article-title":"Treatment of anxiety symptoms with adjunctive aripiprazole in depressed patients taking serotonin reuptake inhibitors","volume":"86","author":"Adson","year":"2005","journal-title":"Journal of Affective Disorders"},{"issue":"6","key":"10.1002\/14651858.CD008120.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1017\/S109285290001676X","article-title":"Aripiprazole as a augmentation treatment of refractory generalized anxiety disorder and panic disorder","volume":"13","author":"Hoge","year":"2008","journal-title":"CNS Spectrums"},{"issue":"2","key":"10.1002\/14651858.CD008120.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.jcp.0000248620.34541.bc","article-title":"An open label trial of aripiprazole augmentation for treatment resistant generalized anxiety disorder","volume":"27","author":"Menza","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-244X-9-25","article-title":"A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomised, single-blind study","volume":"9","author":"Prosser","year":"2009","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008120.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.jcp.0000195108.01898.17","article-title":"Olanzapine augmentation in treatment resistant panic disorder: a 12 week fixed-dosed open-label-trial","volume":"26","author":"Sepede","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008120.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jad.2008.10.005","article-title":"Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety","volume":"115","author":"Sheehan","year":"2009","journal-title":"Journal of Affective Disorders"},{"issue":"3","key":"10.1002\/14651858.CD008120.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4088\/JCP.v67n0307","article-title":"An open label trial of risperidone augmentation for refractory anxiety disorders","volume":"67","author":"Simon","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008120.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004714-200204000-00016","article-title":"The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery","volume":"22","author":"Wilner","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008120.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-200501000-00002","article-title":"Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients","volume":"20","author":"Worthington","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008120.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.janxdis.2008.12.004","article-title":"Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia","volume":"23","author":"Donahue","year":"2009","journal-title":"Journal of Anxiety Disorders"},{"issue":"2","key":"10.1002\/14651858.CD008120.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JCP.0b013e3181d21951","article-title":"Ziprasidone treatment of refractory gneralized anxiety disorder : a placebo-controlled, double-blind study","volume":"30","author":"Lohoff","year":"2010","journal-title":"Journal of Clinical Psychopharnmacology"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0024|cit24","unstructured":"Goddard A AstraZeneca A study of quetiapine SR (Seroquel SR) to treat SSRI-resistant, comorbid panic disorder patients [NCT00619892] http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00619892 accessed on 10 March 2009"},{"issue":"11","key":"10.1002\/14651858.CD008120.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: A comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0027|cit27","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 3rd edition (DSM III)","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0028|cit28","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 3rd edition - revised (DSM-III-R)","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0029|cit29","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cpr.2005.07.003","article-title":"The empirical status of cognitive-behavioral-therapy: A review of meta-analyses","volume":"1","author":"Butler","year":"2006","journal-title":"Clinical Psychology Review"},{"issue":"9","key":"10.1002\/14651858.CD008120.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.mp.4001852","article-title":"Treatment-resistant anxiety disorders","volume":"11","author":"Bystritsky","year":"2006","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of one-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1017\/S0033291796004217","article-title":"The Brief Social Phobia Scale: a psychometric evaluation","volume":"27","author":"Davidson","year":"1997","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Der-Simonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD008120.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004714-200106000-00011","article-title":"Psychological and pharmacological treatments of social phobia: a meta-analysis","volume":"21","author":"Fedoroff","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analysis can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD008120.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4088\/JCP.v67n0902","article-title":"Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review","volume":"67","author":"Gao","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4088\/JCP.v67n0305","article-title":"The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"67","author":"Grant","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0044|cit44","volume-title":"Clinical Global Impressions - ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"British Journal of Medical Psychology"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0046|cit46","first-page":"56","article-title":"A rating scale of depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archpsyc.55.12.1133","article-title":"Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome","volume":"12","author":"Heimberg","year":"1998","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"7414","key":"10.1002\/14651858.CD008120.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008","DOI":"10.1002\/9780470712184"},{"issue":"4","key":"10.1002\/14651858.CD008120.pub2-BIB0051|cit51","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005473.pub2","article-title":"Pharmacotherapy augmentation strategies in treatment resistant augmentation disoders","author":"Ipser","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008120.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005170.pub2","article-title":"Pharmacotherapy for anxiety disorder in children and adolescents","author":"Ipser","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/archpsyc.1994.03950010008002","article-title":"Lifetime and 12-month prevalence of DSM-III psychiatric disorders in the United States","volume":"51","author":"Kessler","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008120.pub2-BIB0054|cit54","article-title":"Second-generation antipsychotic drugs for obsessive compulsive disorder","author":"Komossa","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9657","key":"10.1002\/14651858.CD008120.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","article-title":"Social Phobia","volume":"22","author":"Liebowitz","year":"1987","journal-title":"Modern Problems in Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1176\/ps.2006.57.12.1738","article-title":"Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden","volume":"57","author":"Munk-J\u00f8rgensen","year":"2006","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1002\/14651858.CD008120.pub2-BIB0061|cit61","first-page":"309","article-title":"Medical evaluation of panic attacks","volume":"48","author":"Raj","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008120.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11920-003-0062-9","article-title":"Treatment for mood and anxiety disorders: quetiapine and aripiprazole","volume":"5","author":"Sajatovic","year":"2003","journal-title":"Current Psychiatry Reports"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ajp.154.11.1571","article-title":"Multicenter collaborative Panic Disorder Severity Scale","volume":"154","author":"Shear","year":"1997","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008120.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/070674370605100206","article-title":"Prevalence and incidence studies of anxiety disorders: A systematic review of the literature","volume":"51","author":"Somers","year":"2006","journal-title":"Canadian Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008120.pub2-BIB0065|cit65","article-title":"Pharmacotherapy for social anxiety disorder","author":"Stein","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0066|cit66","first-page":"1","article-title":"Seroquel led antipsychotics sales in 2006","volume":"35","author":"Vital","year":"2007","journal-title":"Clinical Psychiatric News"},{"key":"10.1002\/14651858.CD008120.pub2-BIB0067|cit67","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)","author":"World Health Organisation","year":"1992"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008120.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T05:32:07Z","timestamp":1685856727000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008120.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,8]]},"references-count":67,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008120.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,8]]}}}